SCHEDULE 13G/A: Aquilo Capital Entities Disclose Significant Stake in Precision Biosciences, Nearing 10% Ownership

Aquilo Capital, L.P., Aquilo Capital Management, LLC, and Marc Schneidman have filed an amended Schedule 13G, disclosing beneficial ownership of up to 9.9% of Precision Biosciences Inc.'s common stock.

Summary

• Aquilo Capital, L.P. beneficially owns 521,372 shares of Precision Biosciences Inc. common stock, representing approximately 6.6% of the class.
• This ownership for Aquilo Capital, L.P. includes 312,372 common shares and 209,000 shares issuable upon the exercise of warrants.
• Aquilo Capital Management, LLC and Marc Schneidman each beneficially own 791,862 shares, representing approximately 9.9% of the common stock.
• Their ownership includes 536,376 common shares and 255,486 shares issuable upon the exercise of warrants.
• The beneficial ownership percentages are calculated based on 7,671,059 shares of common stock outstanding as of October 31, 2024, as reported in the Issuer's 10Q filed on November 4, 2024, plus the respective warrant shares.
• A blocker provision in the warrants prevents the holder from exercising warrants to the extent that, together with affiliates, ownership would exceed 9.99% of the common stock, resulting in 57,014 warrant shares being excluded from the reported beneficial ownership for Aquilo Capital Management, LLC and Marc Schneidman.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently indicates a positive or negative sentiment towards the company's operational or financial performance.

Future Outlook

The document does not provide any forward-looking statements or guidance from Precision Biosciences Inc. or the reporting entities regarding the company's future performance or strategy.

Management Comments

• The Reporting Persons certify that, to the best of their knowledge and belief, the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired or held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing reflects a routine disclosure of passive institutional ownership in a publicly traded biotechnology company. Such filings provide transparency on significant shareholder stakes, which can be of interest to other investors tracking institutional confidence or potential future liquidity events.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, offering insight into the composition of the company's shareholder base.

Key Dates

Keywords

Precision Biosciences Inc., Aquilo Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Ownership, SEC Filing, Biotechnology